Phase II Study of Imatinib in Patients With Recurrent Gliomas of Various Histologies: A European Organisation for Research and Treatment of Cancer Brain Tumor Group Study
Open Access
- 1 October 2008
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (28), 4659-4665
- https://doi.org/10.1200/jco.2008.16.9235
Abstract
Purpose: To evaluate the safety and the efficacy of imatinib in recurrent malignant gliomas. Patients and Methods: This was a single-arm, phase II study. Eligible patients had recurrent glioma after prior radiotherapy with an enhancing lesion on magnetic resonance imaging. Three different histologic groups were studied: glioblastomas (GBM), pure/mixed (anaplastic) oligodendrogliomas (OD), and low-grade or anaplastic astrocytomas (A). Imatinib was started at a dose of 600 mg/d with dose escalation to 800 mg in case of no toxicity; during the trial this dose was increased to 800 mg/d with escalation to 1,000 mg/d. Trial design was one-stage Fleming; both an objective response and 6 months of progression-free survival (PFS) were considered a successful outcome to treatment. Results: A total of 112 patients (51 patients with GBM, 25 patients with A, and 36 patients with OD) were enrolled. Imatinib was in general well tolerated. The median number of cycles was 2.0 (range, 1 to 43 cycles). Five patients had an objective partial response, including three patients with GBM; all had 6 months of PFS. The 6-month PFS rate was 16% (95% CI, 8.0% to 34.0%) in GBM, 4.0% (95% CI, 0.3% to 15.0%) in OD, and 9% (95% CI, 2.0% to 25.0%) in A. The exposure to imatinib was significantly lower in patients using enzyme-inducing antiepileptic drugs. The presence of ABCG2 point mutations were not correlated with pharmacokinetic findings. No somatic activating mutations of KIT or platelet-derived growth factor receptor–A or –B were found. Conclusion: In the dose range of 600 to 1,000 mg/d, single-agent imatinib is well tolerated but has limited antitumor activity in patients with recurrent gliomas.This publication has 31 references indexed in Scilit:
- Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: A Pediatric Brain Tumor Consortium report1Neuro-Oncology, 2007
- AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma PatientsCancer Cell, 2007
- Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08Clinical Cancer Research, 2006
- Characterization of an imatinib-sensitive subset of high-grade human glioma culturesOncogene, 2006
- Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient seriesAnnals of Oncology, 2005
- Distribution of STI-571 to the Brain Is Limited by P-Glycoprotein-Mediated EffluxThe Journal of pharmacology and experimental therapeutics, 2002
- Constitutive Expression of Growth-related Oncogene and Its Receptor in OligodendrogliomasNeurosurgery, 2001
- Constitutive Expression of Growth-related Oncogene and Its Receptor in OligodendrogliomasNeurosurgery, 2001
- Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loopInternational Journal of Cancer, 1995
- Activated platelet‐derived growth factor autocrine pathway drives the transformed phenotype of a human glioblastoma cell lineJournal of Cellular Physiology, 1994